Dr. Tahir Latif, MD
Claim this profileUniversity of Cincinnati Cancer Center-UC Medical Center
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
11 reported clinical trials
32 drugs studied
Area of expertise
1Lymphoma
CD10 positive
BCL6 positive
CXCL13 positive
2Diffuse Large B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Tahir Latif, MD is currently running
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting1 award Phase 25 criteria
IMPT-314
for Non-Hodgkin's Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Recruiting1 award Phase 1 & 2
More about Tahir Latif, MD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tahir Latif, MD has experience with
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- Brentuximab Vedotin
- ALLO-647
- ALLO-501A
- Irinotecan
Breakdown of trials Tahir Latif, MD has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tahir Latif, MD specialize in?
Tahir Latif, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD10 positive patients, or patients who are BCL6 positive.
Is Tahir Latif, MD currently recruiting for clinical trials?
Yes, Tahir Latif, MD is currently recruiting for 2 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tahir Latif, MD has studied deeply?
Yes, Tahir Latif, MD has studied treatments such as Rituximab, Autologous Hematopoietic Stem Cell Transplantation, Brentuximab Vedotin.
What is the best way to schedule an appointment with Tahir Latif, MD?
Apply for one of the trials that Tahir Latif, MD is conducting.
What is the office address of Tahir Latif, MD?
The office of Tahir Latif, MD is located at: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio 45219 United States. This is the address for their practice at the University of Cincinnati Cancer Center-UC Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.